Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bmy-7378. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 11/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 10/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bmy-7378 SCHEMBL32690868 | 0.99 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| Bmy-7378 SCHEMBL6017145 | 0.99 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| Hydrochloric Acid SCHEMBL10517891 | 0.86 | HTR1A (0.76) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| SCHEMBL10521435 | 0.85 | HTR1A (0.75) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| Hydrochloric Acid SCHEMBL7655300 | 0.85 | HTR1A (0.83) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| SCHEMBL14416822 | 0.84 | HTR1A (0.78) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| SCHEMBL7655340 | 0.83 | HTR1A (0.85) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| SCHEMBL10517262 | 0.83 | HTR1A (0.76) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| SCHEMBL6751064 | 0.81 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DALDH1A1 | |
| Hydrochloric Acid SCHEMBL10519410 | 0.81 | HTR1A (0.69) | HTR1AADRA1BADRA1AADRA1DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4634193-A1 | SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4634194-A1 | SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | disclosed |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | Karuna Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3261640-B1 | 5HT AGONISTS FOR TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-20130149715-A1 | G-PROTEIN-CONJUGATED RECEPTOR HAVING ALTERED LIGAND AFFINITY, AND USE THEREOF | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| CN-101679500-B | G-protein-conjugated receptor having altered ligand affinity, and use thereof | PHARMACOME L L C | 2013-05-15 | — | — | CN | disclosed |
| US-20120115778-A1 | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-05-10 | — | — | US | disclosed |
| US-8173378-B2 | Methods of using an alpha-1-adrenergic receptor having altered ligand affinity | PHARMACOME LLC (JP) | 2012-05-08 | — | — | US | disclosed |
| WO-2011009012-A1 | METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2 | COLUMBIA UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100120068-A1 | G-protein-conjugated receptor having altered ligand affinity, and use thereof | PHARMACOME LLC (JP) | 2010-05-13 | — | — | US | disclosed |
| CN-101679500-A | G-protein-conjugated receptor having altered ligand affinity, and use thereof | PHARMACOME LLC | 2010-03-24 | — | — | CN | disclosed |
| EP-2154154-A1 | G-PROTEIN-CONJUGATED RECEPTOR HAVING ALTERED LIGAND AFFINITY, AND USE THEREOF | Pharmacome LLC (JP) | 2010-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | HTR1A 212/4885ADRA1B 297/4885ADRA1A 172/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | HTR1A 4523/4885ADRA1B 3727/4885ADRA1A 3732/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HTR1A 156/4885ADRA1B 262/4885ADRA1A 223/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | HTR1A 10/4885ADRA1B 193/4885ADRA1A 255/4885 |
| US-20120115778-A1 | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 | HTR1A, HTR2B, HTR2A | HTR1A 1/4885ADRA1B 161/4885ADRA1A 193/4885 |
| US-12447144-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | HTR1A 1/4885ADRA1B 130/4885ADRA1A 60/4885 |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | CHRM3, CHRM4, CHRM2 | HTR1A 77/4885ADRA1B 62/4885ADRA1A 56/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | HTR1A 63/4885ADRA1B 33/4885ADRA1A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.